Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by MML Investors Services LLC

MML Investors Services LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 41.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,533 shares of the biopharmaceutical company's stock after purchasing an additional 2,218 shares during the quarter. MML Investors Services LLC's holdings in Regeneron Pharmaceuticals were worth $5,366,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. MetLife Investment Management LLC boosted its position in Regeneron Pharmaceuticals by 1.0% during the fourth quarter. MetLife Investment Management LLC now owns 28,240 shares of the biopharmaceutical company's stock worth $20,116,000 after purchasing an additional 273 shares in the last quarter. Natixis raised its stake in shares of Regeneron Pharmaceuticals by 66.9% during the 4th quarter. Natixis now owns 91,044 shares of the biopharmaceutical company's stock worth $64,853,000 after buying an additional 36,481 shares during the period. Norinchukin Bank The lifted its position in shares of Regeneron Pharmaceuticals by 8.9% during the 4th quarter. Norinchukin Bank The now owns 5,810 shares of the biopharmaceutical company's stock valued at $4,139,000 after buying an additional 475 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its stake in Regeneron Pharmaceuticals by 39.0% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 4,619 shares of the biopharmaceutical company's stock valued at $3,290,000 after acquiring an additional 1,297 shares during the period. Finally, Capital International Inc. CA increased its holdings in Regeneron Pharmaceuticals by 9.9% in the 4th quarter. Capital International Inc. CA now owns 70,605 shares of the biopharmaceutical company's stock worth $50,294,000 after acquiring an additional 6,380 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 1.4 %

Shares of NASDAQ REGN traded up $8.22 during trading on Monday, reaching $610.86. The stock had a trading volume of 1,175,211 shares, compared to its average volume of 726,457. The business's 50-day moving average price is $637.38 and its 200-day moving average price is $721.91. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The company has a market cap of $66.78 billion, a P/E ratio of 15.96, a PEG ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $11.86 earnings per share. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on REGN shares. Bernstein Bank dropped their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Sanford C. Bernstein decreased their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research note on Monday, March 31st. Finally, The Goldman Sachs Group lowered their target price on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $945.32.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.